How to Cite
Abstract
Hemithyroidectomy, according to surgical societies guidelines, is still the therapy of choice in patients with papillary microcarcinoma, with excellent results and a very low complication rate. The disease can be treated only by surgery. And active monitoring should be carried out only under well-defined and controlled conditions. Total thyroidectomy is indicated in patients with multifocal carcinoma, extrathyroidal tumor growth, hereditary tumors (FNMTC), as well as in children and adolescents. In our case, systematic lymphadenectomy is provided according to radiological indications or in case of suspicion of metastatic damage to lymph nodes detected intraoperatively, however, in case of relapse disease, due to the high probability of recurrent nerve damage due to reoperation and the advantage of frozen section pathology examination of intraoperative lymph nodes, the latter is actively used to increase the rate of further recovery in patients of our clinic and in order to maintain the quality of life.
References
Bethesda MD. A Snapshot of Thyroid Cancer: Incidence and mortality.National Cancer Institute. 2014. Available at: https://www.cancer.gov/research/progress/snapshots/ yroid .
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–22. [PubMed] [Google Scholar]
Hedinger CE, Williams ED World Health Organization. 2nd ed. Berlin: Springer; 1993. Histological typing of thyroid tumours; p. 66. [Google Scholar]
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. [PMC free article] [PubMed] [Google Scholar]
Miyauchi A, Ito Y, Oda H. Insights into the Management of Papillary Microcarcinoma of the Thyroid. Thyroid.2018;28:23–31. [PMC free article] [PubMed] [Google Scholar]
Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol. 2018;44:307–315. [PubMed] [Google Scholar]
Yu XM, Lloyd R, Chen H. Current treatment of papillary thyroid microcarcinoma. Adv Surg. 2012;46:191–203.[PubMed] [Google Scholar]
Kwon H, Oh HS, Kim M, Park S, Jeon MJ, Kim WG, et al. Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea. J Clin Endocrinol Metab. 2017;102:1917–25. [PubMed] [Google Scholar]
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–5. [PMC free article] [PubMed] [Google Scholar]
Wang TS, Goffredo P, Sosa JA, Roman SA. Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg. 2014;38:2297–303. [PubMed] [Google Scholar]
Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21:3844–52. [PubMed] [Google Scholar]
Rosato L, Pacini F, Panier Suffat L, Mondini G, Ginardi A, Maggio M, et al. Post-thyroidectomy chronic asthenia: self-deception or disease? Endocrine. 2015;48:615–20. [PubMed] [Google Scholar]
Miyauchi A. Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid. World J Surg. 2016;40:516–22. [PMC free article] [PubMed] [Google Scholar]
Musholt TJ, Fottner C, Weber MM, Eichhorn W, Pohlenz J, Musholt PB, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg. 2010;34:2595–603. [PubMed] [Google Scholar]
Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer. 2015;22:159–68. [PMC free article] [PubMed] [Google Scholar]
Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254:653–60. [PubMed] [Google Scholar]
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95. [PubMed] [Google Scholar]
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–7.[PubMed] [Google Scholar]
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53. [PubMed] [Google Scholar]
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002. [Google Scholar]
Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas. Cancer. 1987;60:1767–70. [PubMed] [Google Scholar]
Giordano D, Gradoni P, Oretti G, Molina E, Ferri T. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol. 2010;35:118–24. [PubMed] [Google Scholar]
Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89:3713–20. [PubMed] [Google Scholar]
Bernet V. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab. 2010;95:3586–92. [PubMed] [Google Scholar]
Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.Surgery. 2008;144:980–7. [PubMed] [Google Scholar]
Baudin E, Travagli JP, Ropers J, Mancusi F, BrunoBossio G, Caillou B, et al. Microcarcinoma of the thyroidngland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553–9. [PubMed] [Google Scholar]
Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40. [PubMed] [Google Scholar]28. Perros P, Boelaert K, Colley S, Evans C, Evans RM,
Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 2014;81(Suppl 1):1–122. [PubMed] [Google Scholar]
AWMF. Operative Operative Therapie maligner Schilddrüsenerkrankungen. 2012. [Accessed Dec 26, 2018]. Available at: https://www.aco-asso.at/wp/wp-content/uploads/2014/01/Leitlinien-SDCA.pdf .
Hillenbrand A, Varhaug JE, Brauckhoff M, Pandev R, Haufe S, Dotzenrath C, et al. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg. 2010;395:851–8. [PubMed] [Google Scholar]
Lee CR, Park S, Kang SW, Lee J, Jeong JJ, Nam KH, et al. Is familial papillary thyroid microcarcinoma more aggressive than sporadic form? Ann Surg Treat Res. 2017;92:129–35. [PMC free article] [PubMed] [Google Scholar]
Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution. Surgery. 2017;161:485–92. [PubMed]
[Google Scholar]
Gschwandtner E, Klatte T, Swietek N, Bures C, Kober F, Ott J, et al. Increase of papillary thyroid microcarcinoma
and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients. Surgery. 2016;159:503–11. [PubMed] [Google Scholar]
Sisli Etfal Hastan Tip Bul. 2018; Surgical Treatment in Papillary Thyroid Microcarcinoma Fatih Tunca,1 Ýsmail Cem Sormaz,1 Ahmet Yalýn Ýþcan,2 and Yasemin Giles Þenyürek1 [www.ncbi.nlm.nih.gov/pmc/articles/PMC7406556/]